In vivo and in vitro estrogenic and progestagenic actions of Tibolone

In vivo and in vitro estrogenic and progestagenic actions of Tibolone

Estrogen and progestin combination in hormone replacement therapy (HRT) increases the incidence of breast cancer, but decreases the endometrial cancer risk of unopposed estrogen. Therefore, a SERM such as Tibolone, that delivers the beneficial, but not the adverse side effects, of steroid hormones w...

Full description

Bibliographic Details
Main Authors: ANIL SADARANGANI, ANA MARÍA SALGADO, SUMIE KATO, MAURICIO PINTO, ANDRÉS CARVAJAL, CAROLINA MONSO, GARETH I OWEN, PILAR VIGIL
Format: Article
Language:English
Published: BMC 2005-01-01
Series:Biological Research
Subjects:
breast/endometrium cancer
estrogenic
HRT
progestagenic & tibolone
Online Access:http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0716-97602005000200014

Internet

http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0716-97602005000200014

Similar Items